NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Dyadic International, Inc. DYAI
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$3.1M
▼ 11.6% vs FY2024
EPS · FY25
$-0.23
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-397.8%
Net margin · FY25
-238.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.1M
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 238 cents on every revenue dollar this year.
Per share
USD -0.23
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-397.8%
Return on equity, FY2025
ROE
Operating margin-232.8%
Net margin-238.3%
Return on assets-74.1%
Each USD of equity lost 398 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+14.0% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+1.8%
+14.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.04B
Shares outstanding, FY2025
Change, 5 years+31.6%
Change, 10 years—
The share count grew 32% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 9.9M
total assets, end of FY2025
Total assetsUSD 9.9M
EquityUSD 1.2M
CashUSD 4.6M
Current ratio2.68×
Equity funds 12% of total assets.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
·
·
·
·
·
·
Income tax $B
·
·
·
·
0.0
0.0
0.0
−0.0
−0.0
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−0.23
−0.20
·
·
−0.47
−0.34
−0.31
−0.21
−0.07
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
−397.8
−139.2
−80.1
−66.1
−55.8
−29.0
−21.2
−12.3
−4.0
Shares out B
0.04
0.03
0.03
0.03
0.03
0.03
0.03
0.03
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed